Thymosin Alpha-1 + KPV

Where the name "Thymosin Alpha-1 + KPV" comes from

This is a market and community name, not a name the literature uses. Peptide Health Lab neither coined it nor endorses it, and the page exists because the phrase is what people type into a search box.

Where it came from is undocumented, and that is a finding rather than an omission. A PubMed search for (thymosin alpha 1) AND (KPV) on 1 September 2026 returned 0 records; so did "thymosin alpha 1"[All Fields] AND "KPV"[All Fields], (KPV) AND (thymosin), (KPV) AND (thymus OR thymic), (thymalfasin) AND (KPV), "Zadaxin"[All Fields] AND "KPV"[All Fields], (thymosin alpha-1) AND (lysine-proline-valine), and (thymosin alpha 1) AND (alpha-MSH), each run the same day. None of those eight searches returns a record that proposes this pairing, defines it, or names it. What the searches do return, once the terms are loosened far enough, is a single 2025 short review of host defence peptides for inflammatory bowel disease which lists KPV under alpha-melanocyte-stimulating hormone and an LL-37-Talpha1 construct under cathelicidins, in one enumerated sentence of candidate molecules, and administers nothing to anything.^[9] A review that names two compounds in one list has not studied them together, and this page says so in the same breath as the count.

Dosing and protocol ranges for each component live on the individual compound pages, not here. This page carries none.

What's in it and why people combine them

The two components have almost opposite evidence shapes, and the reason the pairing sounds plausible is that a reader tends to average them.

Thymosin alpha-1 is a 28-residue peptide isolated from thymic extract, and it is none of the other molecules with "thymosin" in the name. Thymosin fraction 5 yielded several distinct peptides — thymosin alpha-1, polypeptide beta-1 and thymosin beta-4 among them — and a review of the beta-thymosins is explicit that none of the isolated peptides turned out to be a thymic hormone in the sense the name implied, and that they are separate molecules with diverse functions.^[3] Thymosin alpha-1 is not thymalin, not thymosin beta-4, and not TB-500. Evidence about any of those is not evidence about this one, and the confusion is common enough that the distinction is worth stating before anything else.

KPV is Lys-Pro-Val, the carboxy-terminal tripeptide of the 13-residue hormone alpha-melanocyte-stimulating hormone — and the parent hormone's evidence is not the fragment's. A keratinocyte study ran alpha-MSH, KPV, the D-isomer KP-D-V and adrenocorticotropic hormone side by side: none of the four elevated cyclic AMP in either immortalized or normal human keratinocytes, and all four produced rapid intracellular calcium responses, but only in the presence of an adenosine agonist that inhibits the cyclic AMP pathway.^[2] On those two readouts the fragment and the hormone behaved alike — and that is a result about the fragment only because the fragment was itself put in the assay, not because the hormone was. That study is the clearest demonstration that the two are handled as distinct entities to be tested separately rather than assumed equivalent, and being run side by side in one experiment is not the same as evidence for the fragment: a reader who has been shown alpha-MSH data has not thereby been shown KPV data.

KPV's own best-developed work is rodent and cell. Uptake runs through PepT1, a di/tripeptide transporter expressed at low levels in the healthy colon and induced during intestinal inflammation, and oral administration reduced the incidence of two induced colitis models in mice.^[4] That is a coherent mechanism, and a PubMed search for (KPV OR lysine-proline-valine) AND (clinical trial[pt] OR randomized controlled trial[pt]) on 1 September 2026 returned 7 records, none of them a study of the tripeptide — so the mechanism has not been carried into a person anywhere the index can see.

What the evidence says about the combination

A PubMed search for (thymosin alpha 1) AND (KPV) on 1 September 2026 returned 0 records, so no indexed study has administered these two together — in any species, for any endpoint. Seven further two-component shapes run against PubMed the same day — reproduced verbatim in the first section above — returned 0 records each. A ninth, (thymosin alpha 1 OR thymalfasin) AND (KPV OR lysine-proline-valine) AND (combination OR combined OR co-administration OR co-administered OR administered together), returned 0 on the same day. A tenth, (thymosin alpha 1) AND (KPV) AND (immune), returned 0. A ClinicalTrials.gov search for the term "thymosin alpha 1 KPV" on 1 September 2026 returned totalCount 0, against a control search for "thymosin alpha 1" alone returning 66 studies on the same day — so the empty result is a fact about the registry's contents and not about the query failing.

Loosening further does not help. (thymosin alpha 1) AND (melanocortin) on 1 September 2026 returned 5 records, all published between 1983 and 1992 on thymosin's effects on pituitary and adrenal hormone release, none of which names KPV. (thymalfasin) AND (alpha-MSH) returned 0. The single record that names both compounds anywhere is the 2025 host-defence-peptide review, which enumerates them in separate families within one sentence and reports no experiment combining them.^[9]

An additivity test between these two components would have surfaced in the two-component searches, and all ten of them — beginning with (thymosin alpha 1) AND (KPV) — returned 0 records on PubMed on 1 September 2026, so there is no such test to report in either direction. What exists is a mechanistic story a reader can assemble — a thymic immunomodulator alongside an anti-inflammatory tripeptide — and a mechanistic story is not a result. The claim for the pairing on this page is graded anecdotal because there is nothing to grade.

Where the evidence is weak

The component with the real trials is the component whose trials missed. The largest randomized trial ever run on thymosin alpha-1 randomized 1,106 adults with sepsis across 22 centres and found 28-day all-cause mortality of 23.4% against 24.1%, hazard ratio 0.99, P=0.93, with no secondary or safety outcome separating; the authors' own conclusion is that there was no clear evidence of benefit. Prespecified subgroup interactions by age and by diabetes were reported, and a subgroup interaction inside a trial whose primary endpoint was not met is a hypothesis rather than a finding.^[8] The largest hepatology trial randomized 690 patients with HBV-related compensated cirrhosis and found the cumulative incidence of decompensation, liver cancer or death similar between groups; the authors then described a tendency to inhibit cancer development, which is a softer description of the same non-significant result rather than a second one.^[6]

That trial lists the peptide's commercial sponsor among its funders. Its competing-interests statement records support from SciClone Pharmaceuticals for the submitted work, and grants or consultancy fees to a majority of the named authors. All of that is disclosed rather than hidden, and it means the result cannot be described as independent of the sponsor.^[8] The Italian marketing authorisation described in the anti-doping section below is held by a company of the same name registered in Italy.

The largest observational dataset points the other way. In a multicentre cohort of 306 treated and 1,976 untreated patients with COVID-19, every crude outcome was significantly worse in the treated group, and after adjustment the association with a higher non-recovery rate persisted, with the largest association among patients admitted to intensive care. Treatment was allocated by clinicians rather than randomly, so confounding by indication is a live alternative explanation — and that is a reason to hold the result loosely, not a reason to leave it out.^[7]

The one credential that would justify putting KPV in an immune combination has a published failed replication attached to it. The 2000 paper reporting antimicrobial activity of alpha-MSH peptides against S. aureus and C. albicans is the paper the immune framing rests on.^[1] In 2009 the same journal published a letter, formally indexed as a Comment on it, reporting microplate growth-inhibition assays on C. albicans in which the authors could not observe any growth-inhibiting effect, and in which repeating the original assay with different C. albicans strains produced only a mild effect, at a concentration far above the picomolar range the original emphasised; an author reply was printed alongside.^[5] The letter reports its assays under the heading of the alpha-MSH peptides rather than separating the hormone from the tripeptide, so what it disputes is the antimicrobial claim the original made for both. Both halves belong on any page that uses that claim at all, and this one does.

KPV's human evidence base is empty as far as this page could search. A PubMed search for (KPV OR lysine-proline-valine) AND (clinical trial[pt] OR randomized controlled trial[pt]) on 1 September 2026 returned 7 records, and reading them shows every one to be an unrelated trial that matched on the letters rather than the molecule — gonadotropins in in vitro fertilisation, neonatal encephalopathy, neonatal bronchopulmonary dysplasia, tumour-response imaging, irreversible electroporation in liver and pancreatic cancer, and videolaryngoscopy. Not an efficacy result, not a safety database, not an exposure measurement. The rodent colitis work is internally coherent and mechanistically specific, and it stops at rodents.^[4] Combining a compound whose human evidence is largely negative with a compound that has no human evidence does not produce a stronger position than either. It produces a page on which the strongest available evidence argues against one component and does not exist at all for the other.

Questions to bring to a provider

The useful version of this conversation starts from the symptom, not from the pairing.

• What is the actual immune problem being described, and does it have a diagnosis? Thymosin alpha-1's randomized evidence sits in hospital populations — 1,106 adults with sepsis^[8] and 690 with HBV-related compensated cirrhosis^[6] — and neither trial enrolled a healthy adult who feels run down.
• Given that the largest trial of this peptide missed its primary endpoint and its largest observational dataset was associated with worse outcomes,^[7] what would have to be true for it to be worth considering ahead of an evaluated option?
• A PubMed search for (KPV OR lysine-proline-valine) AND (clinical trial[pt] OR randomized controlled trial[pt]) on 1 September 2026 returned 7 records and none of them studies the tripeptide. With no human exposure data to start from, what would a clinician monitor, and against what baseline? Everything known about the molecule comes from cell lines and from mice given it by mouth in two induced colitis models.^[4]
• Nanomolar KPV inhibits NF-kappaB and MAP kinase inflammatory signalling and reduces pro-inflammatory cytokine secretion in culture.^[4] What does sustained suppression of those pathways mean for infection risk or immune surveillance in someone already immunosuppressed, on immunosuppressive medication, or with a history of malignancy?
• Which objective measure would show whether anything changed, and over what interval would it be read?

Anti-doping status

Neither component is named on the World Anti-Doping Agency Prohibited List in force for 2026. The List, the 2026 Monitoring Program and the 2026 Explanatory Note were retrieved on 1 September 2026 by way of the United States Anti-Doping Agency's prohibited-list page, which returned HTTP 200 with a browser user-agent string and links the WADA-hosted PDFs; all three PDFs returned HTTP 200. A search of the List text returns 2 occurrences of "thymosin", both belonging to the same S2.3 entry — "Thymosin-ß4 and its derivatives e.g. TB-500", under growth factors and growth factor modulators. Thymosin beta-4 is a separate gene product from thymosin alpha-1, isolated separately from the same crude thymic fraction, and thymosin alpha-1 is not a derivative of it.^[3] "KPV", "melanocortin", "melanocyte" and "MSH" each returned 0 occurrences in all three documents. Both statements are read from the published documents themselves and carry no citation, because a research paper is a source for what the literature shows and is never a source for what a regulator has done.

A compound the List does not name has not thereby been cleared by it, and section S0 is the reason. S0 reads, in its own words, on "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use". The trigger turns on approval by any government's health authority, anywhere — not on United States approval.

For thymosin alpha-1 this page cannot settle the question, and says so instead of guessing. The Gazzetta Ufficiale della Repubblica Italiana, Parte Seconda number 84 of 18 July 2023, retrieved at HTTP 200 on 1 September 2026, records a secondary variation to a marketing authorisation for a human medicinal speciality under Italian Legislative Decree 219/2006: the product is ZADAXIN powder and solvent for injectable solution, the holder is Sciclone Pharmaceuticals Italy S.r.l., the authorisation number is A.I.C. 028364026, and the variation is a Type IB granted on that date. That is a governmental regulatory health authority approval, verified live in 2023. Whether it remains in force in 2026 could not be verified from any primary source in this session: the Italian medicines agency's live product register did not resolve at all, its documented interface path returned HTTP 404, and the European regulator's product database failed at the network layer. Elsewhere the negatives are clean and were run against working controls: the United States drug-label interface returned HTTP 404 for thymalfasin and for thymosin while returning a label for a control compound, and DailyMed returned zero total elements against a database published 31 August 2026 while returning hundreds for a control; the Canadian active-ingredient interface returned an empty list against a control that returned results. So: if the Italian authorisation is still in force, S0's trigger is not met for thymosin alpha-1. This page verified 2023 and could not verify 2026, and therefore asserts no S0 conclusion in either direction. The widely repeated claim that the compound is approved in dozens of countries was not confirmed at any primary regulator here and is not repeated.

For KPV the ordinary reading stands. No approval was found at any regulator searched. The United States Food and Drug Administration's briefing document for the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026, retrieved at HTTP 200 on 1 September 2026, records that KPV-related bulk drug substances were nominated for the 503A bulks list, that the nomination was withdrawn by the nominator, that the agency elected to present the substances anyway, and that it proposed KPV free base and KPV acetate NOT be included on that list. A substance with no approval anywhere, and addressed by no other section of the List, is what that sentence reaches. The compounds printed after "including but not limited to" illustrate the sentence; they do not bound it.

An athlete subject to testing should treat an unapproved injectable as a question for their national anti-doping organization rather than as a settled absence, and nothing above should be read as a statement that either compound is permitted. The List is reissued annually and its sections renumber between editions, so a competing athlete should confirm the current year's list rather than this page.